Impact of Seasonal Malaria Chemoprevention on Immunity Against Malaria Among Children in Northern Benin

Conditions: Plasmodium Malariae Infection, SMC, Immune System Disease

Sex: All

Ages: 6 Months – 59 Months

Healthy volunteers: 1

Enrollment: 440

Sponsor: Université de Parakou

Location: Benin

Summary

This study aims to evaluate the effects of SMC (Seasonal malaria chemoprevention) with Sulfadoxine-Pyrimethamine (SP) and Amodiaquine (AQ) on the evolution of anti-malarial immunity of children and their susceptibility to malarial infection.This is a cross-sectional study on children aged 6 to 59 months with/without SMC in two villages in northern Benin. Sociodemographic and clinical data as well as repeated blood samples will be collected from 440 children (before, during and after treatment). Samples will be analyzed using a Luminex assay to investigate antibody responses to MSP (merozoite surface protein) , Glurp (Glutamate-Rich Protein) and a panel of PfEMP1. qPCR (quantitative polymerase chain reaction) will be used to detect the prevalence of malaria at this period and parasites infecting children will be characterize during the follow up.

Eligibility Criteria

Inclusion Criteria:Aged between 6 and 59 monthsHave been selected and accepted to receive SMC treatment (SP-AQ) in the intervention site and not in the control siteBe able to take drugsExclusion Criteria:Child whose parents will no longer consent at some point in the study for one reason or anotherChildren suffering from a chronic diseaseIntolerance to certain drugs

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05650502). StuddyBuddy aggregates publicly available trial information.